Dextromethorphan/quinidine

Drug Profile

Dextromethorphan/quinidine

Alternative Names: AVP-923; Dextromethorphan HBr/quinidine sulfate; Dextromethorphan hydrobromide/quinidine sulfate; Neurodex; Nuedexta; Quinidine/dextromethorphan; Zenvia

Latest Information Update: 30 Mar 2017

Price : $50

At a glance

  • Originator Center for Neurologic Study
  • Developer Avanir Pharmaceuticals
  • Class Analgesics; Antitussives; Cinchona alkaloids; Morphinans; Quinuclidines; Small molecules
  • Mechanism of Action Cytochrome P 450 enzyme system inhibitors; NMDA receptor antagonists; Norepinephrine plasma membrane transport protein inhibitors; Serotonin plasma membrane transport protein inhibitors; Sigma-1 receptor agonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Emotional lability
  • Phase II Agitation; Drug-induced dyskinesia; Migraine
  • No development reported Neuropathic pain
  • Discontinued Diabetic neuropathies

Most Recent Events

  • 01 Mar 2017 Avanir completes a phase II trial in Migraine in USA (NCT02176018)
  • 08 Jun 2016 Adverse events and efficacy data from the PRISM II trial released by Avanir Pharmaceuticals
  • 22 Sep 2015 Efficacy and adverse events data from a phase II trial inAgitation released by Avanir Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top